<DOC>
	<DOCNO>NCT01233440</DOCNO>
	<brief_summary>The primary objective study assess safety IV administration rIX-FP . Safety evaluate adverse event laboratory change time . The secondary objective study evaluate pharmacokinetics parameter , follow single intravenous dose rIX-FP .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Recombinant Coagulation Factor IX Albumin Fusion Protein Subjects With Hemophilia B</brief_title>
	<detailed_description>This study comprise rIX-FP dose-escalation safety segment ( 25 , 50 75 IU/kg rIX-FP ) , PK evaluation rIX-FP single dose 50 IU/kg , well PK evaluation single dose 50 IU/kg previously give Factor IX ( FIX ) product ( recombinant FIX [ rFIX ] plasma derive FIX [ pdFIX ] ) use reference product .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Male , 12 65 year , body weight ≥ 30 kg ≤ 120 kg Documented severe Hemophilia B ( FIX activity ≤ 2 % ) test central laboratory screen Subjects receive FIX product &gt; 150 exposure day ( EDs ) ( estimate ) No confirm prior history FIX inhibitor ( history positive FIX inhibitor define two consecutive positive test confirmatory test second , separately draw sample shortly previous positive test ) confirm detectable FIX inhibitor ( negative FIX inhibitor define &lt; 0.6 Bethesda Units [ BU ] central laboratory screen Subjects treat ondemand prophylactic therapy Signed Informed Consent/Assent Known hypersensitivity ( allergic reaction anaphylaxis ) FIX product hamster protein Any known congenital acquire coagulation disorder congenital FIX deficiency Platelet count &lt; 100,000/µL Immunocompromised ( CD4 count &lt; 200/mm3 ) , ( HIV positive subject may participate study protease inhibitor antiviral therapy permit , discretion Investigator ) Currently receive IV immunomodulating agent immunoglobulin chronic systemic corticosteroid treatment Serum aspartate aminotransferase ( AST ) serum alanine aminotransferase ( ALT ) concentration &gt; 5 time ( x ) upper limit normal ( ULN ) Serum creatinine &gt; 2 x ULN Evidence thrombosis , include deep vein thrombosis , stroke , pulmonary embolism , myocardial infarction arterial embolus within 3 month prior enrollment Use Investigational Medicinal Product ( IMP ) within 30 day prior first rIXFP administration Experienced lifethreatening bleed episode major surgery orthopedic surgical procedure 3 month prior study entry Subject currently dose and/or regimen FIX would preclude participation study due possible increase risk bleed requirement withhold treatment PK sample period Suspected inability ( e.g. , language problem mental condition ) unwillingness comply study procedure history noncompliance</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>